Abstract: Heparin fractions obtained by nitrous depolymerization, containing at most 150 ppb of total N-nitroso compounds, prepared by subjecting heparins of natural origin which have been depolymerized with a nitrite to the action of UV radiation.

Abstract: Method for obtaining biologically active mucopolysaccharides by controlled depolymerization of heparin, wherein the quantity of products generating nitrous acid is selected so that those products are totally consumed when the desired depolymerization degree is reached.

Abstract: The invention relates to derivatives with a uronic acid structure having substituents selected among a reactive group, a functionalisable group and --OH functions blocked by protective groups. These derivatives are useful for preparing glycosides, particularly enzyme substrates.

Abstract: Short chained ligosaccharides of high structural homogeneity constituted essentially by hexasaccharides of the formula: ##STR1## in which R represents a hydrogen atom or the --SO.sub.3.sup.31 group. These hexasaccharides have a highly selective activity on certain steps in blood coagulation and are useful as anti-thrombotic medicaments.

Abstract: Mucopolysaccharides biologically active and more specific than heparin, particularly with respect to the blood factor Xa. These mucopolysaccharides may be obtained by partial depolymerization, under controlled conditions, of heparin, by the action of a chemical agent such as nitrous acid. The conditions implemented allow the preparation of mucopolysaccharides having a USP titer lower than that of the starting heparin and a Yin-Wessler titer at least equal to that of said heparin. These products may be used particularly as antithrombotic drugs.

Abstract: The oligosaccharides of the invention contain or are constituted by a tetrasaccharide enchainment of the formula: ##STR1## in which R.sub.1 represents an organic anion, R.sub.2 is identical to R.sub.1 or represents a hydrogen atom, N.sub.1 and N.sub.2 represent a functional amino group.

Abstract: The oligosaccharidic fractions of the invention are soluble in an hydro-alcoholic mixture 50/50 (v/v) in which is added 0.5% NaCl, at pH 3.8, are constituted by chains the majority of which have 2 to 14 sugar units, are terminated by end units with a 2,5-anhydromanno structure and are devoid or practically devoid of anti-thrombotic activity.

Abstract: The medicaments of the invention contain in their active principle, oligosaccharides of low molecular weight corresponding to or including heparin fragments.

Abstract: 1,4.alpha.disaccharides of formula: ##STR1## with Z representing a nitrogenous functional group,M hydrogen or a sulphate or acetyl group,R an alkyl radical of 1 to 4 carbon atoms andA functional group such as an acid group, or a derivative.

Abstract: The dextran derivatives have a molecular weight higher than about 5000 daltons and comprise statistically at least about 35% of units substituted by radicals having a COO.sup.- function and at least 3% of units comprising a group of structure ##STR1## wherein R.sub.1 is a single bond; or a ##STR2## group, R.sub.2 is an anion of an inorganic or an organic salt and n is a number from 1 to 4.

Abstract: The invention relates to new N-substituted benzenesulfonamides, the process for their preparation and their use.The compounds according to the invention correspond to the general formula (I): ##STR1## in which: n and m have values from 0 to 4;R.sub.3 and R.sub.4 represent in particular a lower alkyl radical;R.sub.1 and R.sub.2 represent in particular hydrogen atoms, linear or branched alkyl groups having from 1 to 4 carbon atoms;R.sub.5 represents particularly a hydrogen atom, a halogen, the NO.sub.2, NH.sub.2, or CF.sub.3 group;R.sub.6 and R.sub.7 represent in particular a hydrogen atom, an alkyl radical of 1 to 6 carbon atoms.The invention is useful in the preparation of tranquilizing or anxiolytic medicines.

Abstract: The invention relates to a method and composition for thrombolytic treatment. It comprises administering to thrombosis-afflicted patients a low molecular weight heparin in an amount effective to cause lysis of thrombi in vivo.

Abstract: This invention relates to oxalate-free preparations of heparin, particularly in the form of calcium salts of heparin, which can be used for the preparation of injectable solutions of heparin which have long storage life.The invention is also directed to a process for freeing heparin from its oxalate content, such as by fractional precipitations by alcohol in the presence of adjusted amounts of mineral salt, until the heparin precipitated contains less than about 70 ppm of oxalate but may contain less than about 30 ppm, preferably even less than 20 ppm.

Abstract: The invention relates to trisubstituted sulfohalides, the process for their preparation and their use as intermediate products for the manufacture of novel compounds.The trisubstituted sulfohalides according to the invention correspond to the following general formula (I): ##STR1## in which: X is a halogen atom, particularly bromine or preferably chlorine;R.sub.3 and R.sub.4 each represent, independently of one another, a lower alkyl radical having from 1 to 4 carbon atoms, A represents hydrogen, halogen, alkoxy radicals having from 1 to 4 carbon atoms, alkylsulfonyl groups having from 1 to 4 carbon atoms, or the group NO.sub.2, or CF.sub.3.The invention is useful in the manufacture of medicaments.

Abstract: The invention relates to new medicaments having lipid regulating properties and processes for their preparation.The medicaments according to the invention contain as active principle at least one compound, (or its corresponding optical isomer) of the arylsulfonamide type corresponding to the formula: ##STR1## in which: Ar represents an aromatic ring which may if necessary be substituted;n+m+1 is comprised from 3 to 11, being preferably equal to 3,5 or 10, or is comprised from 1 to 11 when Ar represents an aryl group in which at least one of the R.sub.1,R.sub.2 and R.sub.3 radicals is a CF.sub.3 group;R.sub.5 and R.sub.6 represent independently of one another particularly an alkyl radical;R.sub.4 represents the hydroxy group, the radical OR.sub.7 in which R.sub.7 is particularly an alkyl group, the radical NR.sub.8 R.sub.9 in which R.sub.8 and R.sub.9 are identical or different, and represent in particular a hydrogen atom, and form with the nitrogen a nitrogenous heterocyclic ring with 5 or 6 links.

Abstract: 1,4 .alpha. disaccharides of formula: ##STR1## with Z representing a nitrogenous functional group,M hydrogen or a sulphate or acetyl group,R an alkyl radical of 1 to 4 carbon atoms andA a functional group such as an acid group, or a derivative.

Abstract: The invention relates to substitution derivatives of trisaccharide 3-fucosyl-N-acetyl lactosamine and to the immunological applications of these derivatives and of the trisaccharide itself particularly as diagnostic reagent and in therapy.

Abstract: Water soluble biologically active fraction obtainable from the physiologically inter-cellular medium bone-marrow and process for preparing said fraction and the pharmaceutical compositions containing said fraction. The characteristics are notably the following: it is substantially free of the inhibitors having molecular weights lower than 30,000; it is lyophilizable without loss of biological properties; it exhibits the biological activities in the form of a solution having a pH of at least 7; it stimulates H-thymidin incorporation by bone-marrow cells in vitro and in vivo; the water soluble fraction is capable of controlling the immune reactions of a host against allogenic cells or tissue.

Abstract: Mucopolysaccharides biologically active and more specific than heparin, particularly with respect to the blood factor Xa. These mucopolysaccharides may be obtained by partial depolymerisation, under controlled conditions, of heparin, by the action of a chemical agent such as nitrous acid. The conditions implemented allow the preparation of mucopolysaccharides having a USP titer lower than that of the starting heparin and a Yin-Wessler titer at least equal to that of said heparin. These products may be used particularly as antithrombotic drugs.

Abstract: Oligopeptides having no more than 10 amino acids containing the sequence--(N-ter) A--X, --Gly--Y--Gly--X.sub.2 --A (C-ter)having the capacity of interacting with blood platelets and an ability to inhibit the aggregation of platelets induced by a collogen containing substance.